Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer

Journal of Experimental and Clinical Cancer Research

Volumn 20, Issue 3, 2001, Pages 335-340

  Weitberg, A B ^a   Liu, L ^a   Yashar, J ^a   Glicksman, A S ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Long term outcome; NSCLC; Stage IIIA; Trimodality therapy

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DRUG INFUSION; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; THORACOTOMY; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034779025     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): Three year follow-up
2. Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report
3. N2 lung cancer: Outcome in patients with false-negative computed tomographic scans of the chest
4. Multimodality therapy in stage III non-small cell lung cancer
5. The National cancer data base report on lung cancer
6. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease)
7. Nonparametric estimation from incomplete observations
8. Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIa (N2) - Analysis of Cancer and Leukemia Group B Protocol 8935
9. Sagety of trimodality treatment in patients with pathologically staged IIIA (N2) non-small cell lung cancer (NSCLC) utilizing consolidative thoracic irradiation: Results of Cancer and Leukemia Group B)CALGB) Trial 8935
10. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06
11. Evaluation of survival data and two new rank order statistics arising in its consideration
12. Preoperative concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
13. Expanded possibilities for surgical treatment of lung cancer. Survival in stage IIIA disease
14. Phase I/II trial of paclitaxel (TAX), cisplatin (DDP) and radiation therapy stage III non-small cell lung cancer (NSCLC)
15. Cancer statistics, 1997
16. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non small cell lung cancer
17. Combined modality therapy for stage IIIa non-small cell carcinoma of the lung